In contrast, Mitchell et al. found an overall significant difference in return to baseline FEV1% predicted with AUC monitoring (80%) compared to trough monitoring (61%) (p = 0.02); however, this is confounded by higher rates of CFTR modulator use in the AUC cohort, particularly in adults with CF [20]. Here, CFTR is linked to cystic fibrosis.